One of the most pressing biomedical issues is the development of techniques that increase the efficiency of vaccines. In a paper published on April 24, 2008 in the journal Vaccine, a Massachusettss biotechnology company, Cure Lab, Inc. has proposed a new technology for anti-viral vaccination. This technology consists of two major elements. First, each vaccine antigen should be made in two forms. One is easily processed within the organisms cells by an intracellular chopping machine called the proteosome, while another is resistant to the chopping. Thus both these forms of an antigen would be used in combination to elicit a much stronger immune response than either of them would be able to do alone.
Imagine a vaccine that could make a cell within our body produce a viral protein. This is called a recombinant vaccine. Recombinant vaccines give the most hope today as anti-viral and anti-cancer vaccines. They train the immune system to recognize and eliminate first infected or cancerous cells, preventing a disease progression. In order for a recombinant vaccine to be effective, the produced viral protein must be presented by the cell to our immune system. This antigen presentation process is very complex and remains poorly understood.
A few years ago the situation seemed to be simple- said Dr. Alex Shneider, Founder and CEO of Cure Lab, Inc. - Vaccinologists believed that a recombinant vaccine makes the cell able to produce a viral protein. The proteosome cuts this protein into pieces. These pieces are then presented on the cell surface and stimulate immunity. If this was the complete story, life-saving solutions would be so close. A lot of research groups rushed to enhance their vaccines by fusing different viral proteins used in vaccines with specific transport signals directing the proteins to the proteosome. The logic was pretty straightforward. The more protein that would be targeted to a proteosome, the more protein segments generated for
|Contact: Alex Shneider|
Cure Lab, Inc.